Psoriasis Clinical Trials

Find Psoriasis Clinical Trials Near You

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Status: Recruiting
Location: See all (43) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

⁃ The main inclusion criteria include but are not limited to the following:

• Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening.

• Has a diagnosis of active plaque psoriasis or documented history of plaque psoriasis.

• Has history of biologic disease-modifying antirheumatic drug (bDMARD)-naïve or bDMARD-inadequate response/intolerant.

Locations
United States
Arizona
Arizona Arthritis & Rheumatology Associates, P.C. ( Site 5117)
RECRUITING
Sun City
Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120)
RECRUITING
Tucson
California
Medvin Clinical Research - Riverside ( Site 5115)
RECRUITING
Riverside
Cohen Medical Centers ( Site 5111)
RECRUITING
Thousand Oaks
Medvin Clinical Research - Tujunga ( Site 5113)
RECRUITING
Tujunga
Florida
Arthritis and Rheumatic Disease Specialties ( Site 5105)
RECRUITING
Aventura
International Center for Research ( Site 5124)
RECRUITING
Tampa
Maryland
Arthritis and Rheumatism Associates - Rockville ( Site 5127)
RECRUITING
Rockville
Missouri
Kansas City Physician Partners ( Site 5119)
RECRUITING
Kansas City
North Carolina
Joint and Muscle Research Institute ( Site 5108)
RECRUITING
Charlotte
Nebraska
Physician Research Collaboration, LLC ( Site 5102)
RECRUITING
Lincoln
Pennsylvania
Altoona Center for Clinical Research ( Site 5110)
RECRUITING
Duncansville
Hospital of the University of Pennsylvania ( Site 5134)
RECRUITING
Philadelphia
South Carolina
Articularis Healthcare Group dba: Low Country Rheumatology ( Site 5128)
RECRUITING
Summerville
Texas
Greater Houston Rheumatology ( Site 5103)
RECRUITING
Houston
Other Locations
Canada
Centre de Recherche Musculo-Squelettique ( Site 5202)
RECRUITING
Trois-rivières
Chile
CECIM ( Site 8205)
RECRUITING
Santiago
Centro de Estudios GyC ( Site 8206)
RECRUITING
Santiago
Centro Internacional de Estudios Clinicos (CIEC) ( Site 8201)
RECRUITING
Santiago
Clinica Dermacross ( Site 8200)
RECRUITING
Santiago
Enroll SpA ( Site 8203)
RECRUITING
Santiago
Colombia
Clinica de la Costa S.A.S. ( Site 8301)
RECRUITING
Barranquilla
Centro de investigacion en reumatologia y especialidades medicas SAS (CIREEM SAS) ( Site 8306)
RECRUITING
Bogota
Fundación Valle del Lili ( Site 8302)
RECRUITING
Cali
Germany
Rheumatologische Schwerpunktpraxis ( Site 6405)
RECRUITING
Berlin
Rheuma-Research Lausitz ( Site 6409)
RECRUITING
Cottbus
Rheumazentrum Ruhrgebiet ( Site 6400)
RECRUITING
Herne
Poland
MICS Centrum Medyczne Bydgoszcz ( Site 6907)
RECRUITING
Bydgoszcz
Zespół Poradni Specjalistycznych Reumed Filia nr 1 Wallenroda ( Site 6901)
RECRUITING
Lublin
MICS Centrum Medyczne Torun ( Site 6903)
RECRUITING
Torun
MICS Centrum Medyczne Warszawa ( Site 6905)
RECRUITING
Warsaw
Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im.Prof. El. Reicher-ul.Spartanska 1 ( Site 6906)
RECRUITING
Warsaw
Spain
Hospital Vall d' Hebron ( Site 7101)
RECRUITING
Barcelona
Hospital Viamed Santa Elena ( Site 7105)
RECRUITING
Madrid
CHUS - Hospital Clinico Universitario ( Site 7102)
RECRUITING
Santiago De Compostela
Hospital Universitario la Fe ( Site 7107)
RECRUITING
Valencia
Ukraine
Kyiv Railway Clinical Hospital No.2 of Branch Health Center of the Public Joint Stock Company Ukrain ( Site 7401)
RECRUITING
Kiev
Edelweiss Medics ( Site 7409)
RECRUITING
Kyiv
Medical Center of Limited Liability Company Medical Center Consilium Medical ( Site 7415)
RECRUITING
Kyiv
Medical Center Universal Clinic Oberig of Limited Liability Company Kapytal ( Site 7406)
RECRUITING
Kyiv
Lviv Clin Hospital of Planned Treatment Rehabilitation Palliative Care ( Site 7410)
RECRUITING
Lviv
Limited liability company Medical center Health Clinic ( Site 7412)
RECRUITING
Vinnytsia
Municipal Nonprofit Enterprise Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 7400)
RECRUITING
Vinnytsia
Contact Information
Primary
Toll Free Number
Trialsites@msd.com
1-888-577-8839
Time Frame
Start Date: 2026-04-20
Estimated Completion Date: 2030-01-11
Participants
Target number of participants: 140
Treatments
Experimental: High-Dose Regimen
Participants receive a high dose of tulisokibart.
Experimental: Medium-Dose Regimen
Participants receive a medium dose of tulisokibart.
Experimental: Low-Dose Regimen
Participants receive a low dose of tulisokibart and are rerandomized at Week 16 to a medium or high dose of tulisokibart.
Placebo_comparator: Placebo Regimen
Participants receive a matched placebo dose and are rerandomized at Week 16 to a medium or high dose of tulisokibart.
Related Therapeutic Areas
Sponsors
Leads: Merck Sharp & Dohme LLC

This content was sourced from clinicaltrials.gov

Similar Clinical Trials